华邦健康 (002004)

HUAPONT LIFE SCIENCES CO., LTD.

ASZ

Tags

Generic DrugsImmunotherapyAgricultural ChemicalsChemical PharmaceuticalsChemicalsChemical IndustryMedical Aesthetics ConceptInvestments in Newly Listed CompaniesGuozheng Agriculture IndexInfant and Child ConceptTourism ConceptSmart HealthcarePrivate HospitalsBelow Net Asset ValuePest ControlSME 300 IndexShenzhen ConnectSZSE Agriculture IndexSina 100 IndexSZSE 700 IndexSZSE GDP IndexCSI Agriculture IndexSZSE 1000 IndexSZSE Component Index ReturnSME Board Value IndexZhongchuang Value IndexSZSE Materials IndexSZSE Component Materials IndexNew Virus PreventionSpin-off Listing ExpectationGene SequencingSmart HealthcareFTSE Russell ConceptStocks Below Book ValueNEEQMedical AestheticsGene EditingShareholding in NEEQ Select LayerSME Board Composite IndexSZSE Selected IndexSME Board Innovation IndexSME Board Low Volatility IndexPrivate Enterprise Development IndexSZSE Component Index Equal WeightSME Board Dividend IndexSZSE Fundamental 200 IndexZhongchuang Low Volatility IndexCICC 300 IndexSZSE Dividend 50 IndexZhongchuang 400 IndexDividend 200 IndexCSI 1000 Value IndexCSI 1000 Value Stable IndexFundamental 600 IndexAgriculture & Animal Husbandry Theme IndexCSI All-share Materials Sector IndexChongqing

K-Line Chart

No K-line data available

Company NameHuabang Life Health Co., Ltd.
Listing Date2004-06-25
Issue Price9.6RMB
Registered Capital197991.919110k RMB
Legal RepresentativeZhang Songshan
Registered AddressNo. 69, Renhe Xingguang Avenue, Yubei District, Chongqing
IndustryChemical Pharmaceuticals
Main BusinessCovers the R&D, production, and sales of pharmaceutical and agrochemical products, as well as medical services, tourism investment, and operation businesses.
Company ProfileChongqing Huabang Pharmaceutical Co., Ltd. is committed to the R&D, production, and customer service of pharmaceutical products. The company's business primarily focuses on areas such as dermatology and tuberculosis, including products like retinoids, anti-allergy, antifungal, and glucocorticoid drugs. After years of development, Huabang has become 'China's professional clinical dermatology drug supplier' and holds a significant market share in the anti-tuberculosis drug sector, with its formulations and active pharmaceutical ingredients sold in multiple overseas markets. Over the past 20 years, adhering to the principle of 'Quality Products, Healthy Life,' the company has built a strong reputation in dermatology and tuberculosis, establishing itself as 'China's largest clinical dermatology drug supplier' and a 'brand enterprise in the tuberculosis field.' Simultaneously, the company is dedicated to new drug R&D, accumulating a pipeline of blockbuster drugs in areas such as 'respiratory, cardiovascular and cerebrovascular, hematology, and oncology.'

Stock Details

1. Key Indicators

  • Total Shares(W): 197991.92
  • Circulating A-Shares(W): 188161.94
  • Earnings Per Share(RMB): 0.3101
  • Net Assets Per Share(RMB): 4.8986
  • Operating Revenue(W RMB): 908598.84
  • Total Profit(W RMB): 108734.03
  • Net Profit Attributable to Parent(W RMB): 61182.04
  • Net Profit Growth Rate(%): 35.37
  • Weighted Return on Equity(%): 6.3800
  • Operating Cash Flow Per Share(RMB): 0.5720
  • Undistributed Profit Per Share(RMB): 0.9168
  • Capital Reserve Per Share(RMB): 2.7444

2. Main Business

The main business covers:

  • Pharmaceuticals
  • Medical Services
  • Agricultural Chemicals
  • New Materials
  • Tourism

3. Company Basic Information

  • Company Name: Huapont Life Sciences Co., Ltd.
  • Listing Date: 2004-06-25
  • Industry: Chemicals - Agricultural Chemicals
  • Address: No. 69, Xingguang Avenue, Renhe, Yubei District, Chongqing
  • Website: www.huapont.com.cn
  • Company Profile: The predecessor of the company was Chongqing Huapont Biochemical Technology Co., Ltd., which was established on March 11, 1992, as a limited liability company with a registered capital of 500,000 RMB. On September 16, 1994, it was renamed Chongqing Huapont Pharmaceutical Co., Ltd., and its registered capital increased to 1.5 million RMB. On September 19, 2001, Chongqing Huapont Pharmaceutical Co., Ltd. was transformed into Chongqing Huapont Pharmaceutical Co., Ltd., with a registered capital of 66 million RMB.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Chongqing Huibang Zhuoyuan Technology Co., Ltd. General Legal Person 37044.98 19.69
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 3160.93 1.68
3 Shanghai Zhuchi Asset Management Co., Ltd. - Zhuchi New Income Private Equity Investment Fund Phase 6 Private Equity Investment Fund 1808.35 0.96
4 Xi'an Investment Holding Co., Ltd. General Legal Person 1562.50 0.83
5 Southern China Securities 1000 ETF Fund 1448.59 0.77
6 Guotai Haitong CSI 1000 Index Enhanced Securities Investment Fund Class A Fund 388.43 0.21
7 Guotai Haitong CSI 1000 Preferred Stock Initiated Securities Investment Fund Class A Fund 225.90 0.12
8 CITIC Securities CSI 1000 Index Enhanced Securities Investment Fund Class A Fund 53.62 0.03
9 Guotai Haitong Dividend Quantitative Stock Selection Hybrid Securities Investment Fund Class A Fund 48.87 0.03
10 Tianhong CSI Dividend Low Volatility 100 ETF Link Fund Class A Fund 1.65 0.00

5. Concept Sectors

  • Infant & Child Concept
  • Private Hospitals
  • Glyphosate
  • Immunotherapy
  • Smart Healthcare
  • Generic Drugs
  • Pest Control
  • Medical Aesthetics Concept
  • New Materials
  • Tourism Concept
  • Innovative Drugs
  • Margin Trading & Securities Lending
  • Below Net Asset Value
  • Investment in New Listings
  • Spin-off Listing
  • Guozheng Agriculture Index
  • SME 300 Index

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information